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1. General Part 
1.1 Introduction 
1.1.1 Herbal drugs of abuse as legal highs 
Since the implementation of the opium law in the 1960s by the United Nations (UN), 
modern societies tried to control the illicit drug market for reasons of health and to protect 
the community from outgrowths like drug-related crime. The legislative process is 
superior organized by the UN, but every associated country has to execute its national 
depended narcotic acts by its own. In Germany and in many other countries (e.g. USA, 
Switzerland, France), the substances controlled by state were defined in form of a 
whitelist. Consequently, every substance or plant species named by this list is a 
“controlled substance”. In the first four decades, only few substances were controlled and 
the illicit drug market was very stable. For example in the 1970s, consumption of LSD 
and THC was the new trend, in the 1980s, heroin became popular, and in the 1990s, 
MDMA and amphetamine. At the beginning of the 21st century, analogue structures were 
developed to circumvent the legislative process. For instance, different derivatives of 
synthetic cannabinoids (Spice), amphetamines, phenethylamines, and cathinones were 
put on the market [1-9]. These chemicals were sold via the internet as bath salts, plant 
fertilizers, or party pills. Being not (yet) scheduled, they were called “legal highs”. These 
legal highs are single compounds or mixtures of different compounds with more or less 
strong psychoactive effects [7], but without declared ingredients. In addition, different old 
or new “herbal highs” from natural source, often plant species from other cultures, were 
available in the age of globalization. Especially due to the internet advertisement and the 
availability in the trade in goods all around the world, the number of new herbal highs 
increased in the last few years. Examples were magic mushrooms, different cactus 
species, Ayahuasca, baby woodrose (Argyreia nervosa) seeds, Kratom (Mitragyna 
speciosa), yellow hornpoppy (Glaucium flavum), and Kanna (Sceletium tortuosum) [3, 7, 
10-14]. Different preparations such as herbs, extracts, tinctures, as well as fresh plant 
material were offered from single plant species or mixtures. Mostly, the identity of such 
preparations is not confirmed and their pharmacological and toxic effects as well as their 
pharmacokinetic behavior are unknown. Therefore, studies on the metabolism and 
detectability of the metabolites in body samples of such “herbal highs” play an important 
role in clinical and forensic toxicology. 
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1.1.2 Drug metabolism 
Besides the endogenous metabolism, the metabolism of xenobiotics plays an important 
role in biochemistry and toxicology. The metabolizing enzymes are not selective and 
transform various endogenous and exogenous compounds. The resulting metabolites 
can be pharmacologically and toxicologically inactive (biodeactivation/detoxification) or 
active (bioactivation/toxification). Most of these reactions are oxidative reactions, which 
result in increasing hydrophilic properties, which facilitate the renal elimination of these 
compounds. Not all reactions increase hydrophilicity, for example, methylation catalyzed 
by the catechol-O-methyltransferase (COMT) leads to increased lipophilicity. The 
metabolic steps are divided in phase I reactions (functionalization) and phase II reactions 
(conjugation with e.g. glucuronic, sulfuric, or amino acids).  
The characterization of the metabolic fate of xenobiotics is important in clinical and 
forensic toxicology for development of metabolite-based screening approaches [15-18] 
and for assessing the risk of pharmacokinetic interactions or pharmacogenomic 
variations in the effect. In contrast to medicaments, such studies are missing for drugs of 
abuse before consumption. Different in vitro assays and animal models can be used for 
elucidation of the metabolic fate. For example, rat species provide a metabolite pattern 
(qualitatively) similar to humans [2, 19, 20]. These data should be confirmed e.g. by in 
vitro assay with human recombinant enzymes, liver preparations, or hepatocytes. 
Recombinant enzymes allow studying the formation kinetics of single enzymes [21-24]. 
For determination of such enzyme kinetics, the formed metabolite or the degradation of 
the substrate must be quantified [25]. For quantification of the formed metabolites, 
reference standards are needed. In most cases, especially for new drugs of abuse, such 
reference standards are commercially not available. One opportunity is the chemical [25] 
or biochemical synthesis [26-28] of metabolites. If not possible and only one metabolite is 
formed by the particular enzyme, a substrate depletion approach can be used [25, 29-
31]. However, arbitrary units (e.g. the ratio of the LC-MS peak area of the formed 
metabolite vs. that of an internal standard) can also be used for assessing Km, but not for 
Vmax values. 
 
1.1.3 Glaucium flavum alkaloid glaucine 
Glaucine ((S)-5,6,6a,7-tetrahydro-1,2,9,10-tetramethoxy-6-methyl-4H-dibenzo[de,g] 
quinoline, structure given in Fig. 1) is an isoquinoline alkaloid with aporphine structure 
and main ingredient of Glaucium flavum (yellow hornpoppy, Papaveraceae). Other 
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glaucine containing plant species are: Glaucium oxylobum, Croton lechlen, Corydalis 
yanhusu, Nandina domestica [32-36]. Yellow hornpoppy is native in Western Europe, 
North America, and Asia. The latex, typical for Papaveraceae, contains the main 
alkaloids in varying concentration (up to 3 %) depending on environmental factors, 
species variations and plant parts such as root, stem or leave [35]. Other alkaloids of 
yellow hornpoppy are protopine, chelerythrine, magnoflorine, and other minor ones [37]. 
 
 
Fig. 1 Structure of glaucine 
 
Glaucine has anti-inflammatory and antitussive properties, acts as a phosphodiesterase-
4 (PDE4) inhibitor, bronchodilator, calcium channel blocker, and weak dopamine D1 and 
D2 receptor antagonist [38, 39]. The antitussive properties of glaucine in humans were 
investigated in three different clinical studies in comparison to codeine or 
dextromethorphan [40]. Glaucine showed a comparable decrement in cough besides less 
adverse effects and no signs of opiate withdrawal after longer intake [41]. On the other 
hand, case reports of recreational use [42, 43] or side effects of therapeutic use [10] are 
described and show the following symptoms: feeling of tiredness, hallucinations, 
vomiting, dizziness, and decreased blood pressure. Besides its use as antitussive e.g. in 
Bulgaria and Poland, glaucine is part of misused party pills or legal highs [10, 42]. 
 
1.1.4  Sceletium tortuosum alkaloids: mesembrine and mesembrenone 
Sceletium tortuosum belongs to the plant family of Aizoaceae, which is mainly distributed 
in South Africa [44]. Besides the main alkaloids mesembrine ((3aR,7aR)-3a-(3,4-
dimethoxyphenyl)-1-methyloctahydro-6H-indol-6-one) and mesembrenone ((3aR,7aS)-
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3a-(3,4-dimethoxyphenyl)-1-methyl-1,2,3,3a,7,7a-hexahydro-6H-indol-6-one, structures 
given in Fig. 2), several structurally similar compounds were described in the literature, 
for example Δ7-mesembrenone, mesembranol, mesembrenol, tortuosamine, sceletium 
alkaloid A4 etc. [44-46]. These alkaloids were also identified in other 
Mesembryanthemaceae species [44, 45]. The total alkaloid content in 
Mesembryanthemaceae species is very low (1-1.5 %), but Sceletium tortuosum showed 
the highest levels [47]. Geographic and/or growing conditions, age of the plants, as well 
as the process of fermentation influence the alkaloid content and/or composition [48]. 
 
Fig. 2 Structures of mesembrine (A) and mesembrenone (B) 
 
The KhoiSan, previously known as Hottentots, a tribe in South Africa, used the plant 
species after fermentation for their psychoactive effects [47, 48]. The alkaloids were 
tested by Harvey et al. in receptor and enzyme binding studies as well as in cell assays 
[49]. An ethanolic extract showed strong inhibition of 5-HT transporters (IC50, 4.3 µg/mL) 
and of the PDE-4, (IC50, 8.5 µg/mL). Further experiments concluded that mesembrine 
had the lowest Ki value (1.4 nM) for the 5-HT transporter, whereas mesembrenone 
showed the strongest inhibition effects against the PDE-4 (IC50, <1 µM). Further clinical 
trials and experiments in humans confirmed these findings with antidepressive and 
anxiolytic effects of the extract [50, 51]. Khan et al. characterized the pharmacological 
activity of an extract of Sceletium tortuosum and mesembrine itself in Sprague-Dawley 
rats by conditioned place preference, hot plate, forced swim, elevated plus, and rotarod 
tests [52] for elucidating effects on nociception, depression, anxiety, ataxia, abuse 
liability. Differences between the single compound mesembrine and the administration of 
a plant extract containing several other substances were also tested. Mesembrine 
10 
 
caused analgesia, without abuse liabilities or ataxia, whereas the rats treated with the 
extract had higher tendency to fall from the rotating drum (ataxia), and showed higher 
activity swimming behavior (antidepressant activity) in the forced swim test. The authors 
interpreted these findings with the presence of further pharmacological active compounds 
in the extract, which were corresponding to the observed effects. 
Besides the medical or traditional use, different Kanna or “Kougoed” preparations such 
as fermented and dried herbs, powders, capsules, extracts were administered by 
chewing, smoking, or sniffing. The preparations are available in so-called smart shops 
and are misused as legal highs [7]. 
 
1.1.5 Synthesis of phase I metabolites of glaucine 
Due to the four methoxy and the N-methyl groups of glaucine, five isomeric demethyl 
metabolites could be expected as phase I metabolites. Reference standards of these 
metabolites were commercially not available and had to be synthesized. Full synthesis of 
such complex structures would have been too complicated, time consuming and 
expensive. Therefore, less complicated semi-synthesis by demethylation or methylation 
reactions of related structures was an alternative route of synthesis [53-56]. Non-
selective reactions would yield in a complex mixture of isomers, which had to be isolated 
after synthesis. Hence, selective reactions could overcome these problems. In the 
literature, different selective N- or O-demethylation reactions were described for other 
substances [54-56]. An alternative route is the methylation of the phenolic compound 
boldine (2,9-dihydroxy-1,10-dimethoxyaporphine) [53], the main alkaloid of the boldo tree 
(Peumus boldus, Monimiaceae) [57], which was commercial available.  
The corresponding syntheses were described in ref. [25] (see chapter 2.2) 
 
1.1.6 Isolation of mesembrine and mesembrenone 
In the literature, synthesis or isolation procedures for mesembrine and mesembrenone 
have been described [58-61]. The advantage of isolation from plant material was the 
possibility of yielding the main as well as the minor alkaloids in one step. In addition, the 
isolated compounds from plant material have the correct absolute configuration, which is 
not always achieved by chemical synthesis. So far, only few isolation procedures were 
described [60, 61]. Shikanga et al. described a method by using high-speed 
countercurrent chromatography (HSCCC) for the isolation of Sceletium alkaloids [61]. 
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The all-liquid technique might avoid the reported irreversible absorption effects on 
packing material using column chromatography. In case of using acidic silica as 
stationary phase, these absorption effects led to strong tailing effects and therefore, to 
insufficient separation of the alkaloids [61]. Nevertheless, the authors separated the 
alkaloid extract after liquid-liquid extraction (LLE) by column chromatography (CC) with 
silica before separating the CC-fraction with HSCCC [61]. 
The adsorption effects on the silica packing material in CC might be avoided by using 
basic aluminum oxide as stationary phase. Hence, the more easily conducted CC might 
be effective enough to separate the alkaloids in acceptable yield, time and effort. To 
improve the overall yield of isolated alkaloids, the basic LLE were replaced using a 
Soxhlet apparatus, which allowed an exhaustive extraction. 
The corresponding isolation was described in ref. [62] (see chapter 2.3) 
 
1.1.7 Structure elucidation of the metabolites 
For structure elucidation of unknown compounds, different analytical techniques can be 
used such as UV/VIS, IR, NMR, and MS [63]. Each technique has its advantages and 
disadvantages. The choice of the technique mainly depends on compound chemistry, the 
matrix, and the concentration therein. For identification of pure substances, all these 
techniques can be applied in parallel. In case of structure elucidations in drug metabolism 
studies, the application of different gas chromatographic (GC) or liquid chromatography 
(LC) techniques coupled to low or high resolution mass spectrometry (LR-MS or HR-MS) 
provide several advantages, such as high sensitivity and detailed structure information by 
the fragmentation patterns [64-68]. However, the exact position of a metabolically 
introduced or changed substituent cannot be elucidated. NMR would provide this 
information, but cannot be used for the low concentrated metabolites in biomatrix. Thus, 
only chemical synthesis of the proposed metabolites would help in this case. 
The identification of the metabolites of the studied alkaloids was described in refs. [15, 
62] (see chapters 2.1 and 2.3). 
 
 
1.1.8 Toxicological detection 
The detection of new drugs or legal highs in body samples of patients, victims, or 
suspects is a major challenge in clinical and forensic toxicology [5, 17, 20, 69, 70]. Urine 
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screening is the most comprehensive approach covering a broad range of (also low 
dosed) drugs for a longer time than blood, but mostly the metabolites are the analytical 
targets. Thus, the metabolism and the detectability of new drugs in urine have to be 
studied. After having elucidated the metabolite structures after high dose drug application 
and 24 h urine collection, their detectability in rat urine after a common user’s dose using 
the standard urine screening approaches (SUSA) can be assessed [17, 20].  
The detectability in urine of the studied alkaloids was described in refs. [15, 62] (see 
chapters 2.1 and 2.3). 
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1.2 Aims and scopes 
So far, there are no studies available describing the metabolism of Glaucium flavum 
alkaloid glaucine or the Sceletium tortuosum alkaloids mesembrine and mesembrenone. 
Therefore, the aims of the presented study were: 
 
 Identification of the phase I and II metabolites of glaucine in rat urine using GC-
MS and LC-HR-MSn  
 
 Investigation of the detectability of glaucine by the standard urine screening 
approaches 
  
 Confirmation of the phase I metabolites in human liver preparations and 
identification of the involved cytochrome P450 (CYP) isoenzymes 
 
 Synthesis of the phase I metabolites of glaucine for structure confirmation and as 
reference standards for quantitative in vitro enzyme kinetics 
 
 Determination of the CYP enzyme kinetics of glaucine in heterologically 
expressed single CYPs and in HLM and comparison of the results obtained by 
determination of the synthesized metabolites and using arbitrary units 
  
 Isolation of mesembrine and mesembrenone from Sceletium tortuosum as 
reference standards for metabolism studies 
 
 Identification of the phase I and II metabolites of mesembrine and mesembrenone 
in rat urine using GC-MS and LC-HR-MSn  
 
 Confirmation of the phase I metabolites of mesembrine and mesembrenone in 
human liver preparations and identification of the involved CYP isoenzymes 
 
 Investigation of the detectability of mesembrine and mesembrenone by the 
standard urine screening approaches 
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2. Publication of the results 
The results of the studies were published in the following papers: 
2.1 Studies on the metabolism and toxicological detection of glaucine, 
an isoquinoline alkaloid from Glaucium flavum (Papaveraceae), in rat 
urine using GC-MS, LC-MS(n) and LC-high-resolution MS(n) [15]  
(DOI: 10.1002/jms.3112) 
 
  
15 
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2.2 Studies on the in vivo contribution of human cytochrome P450s to 
the hepatic metabolism of glaucine, a new drug of abuse [25]  
(DOI: 10.1016/j.bcp.2013.08.025) 
 
  
17 
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2.3 GC-MS, LC-MSn, LC-high resolution-MSn, and NMR studies on the 
metabolism and toxicological detection of mesembrine and 
mesembrenone, the main alkaloids of the legal high “Kanna” isolated 
from Sceletium tortuosum [62] 
(DOI: 10.1007/s00216-014-8109-9) 
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3. Conclusion  
The presented studies have shown that glaucine was extensively metabolized in rat by 
O- and N-demethylation, N-oxidation, hydroxylation, combinations of them as well as 
glucuronidation and/or sulfation of the phenolic metabolites [15]. In total, 26 phase I and 
21 phase II metabolites could be identified. The synthesized demethylated metabolites, 
the structures of which were confirmed by NMR, allowed their identification in urine 
extracts by comparing their chromatographic retention times and mass spectra. The 
demethylated metabolites were also identified to be the main targets in both 
toxicological urine screening approaches [17, 20]. An intake of glaucine could be 
monitored in rat urine after administration of 2 mg/kg body mass (BM), corresponding to 
a 40 mg human single cough medication dose scaled by dose-by-factor approach 
according to ref. [71]. Using the GC-MS approach, the acetylated mono- and bis-
demethylated metabolites could be detected whereas in the LC-MSn screening 
approach the demethylated metabolites and their glucuronides were the analytical 
targets. The further in vitro studies with HLM confirmed the formation of the mono-
demethylated metabolites in humans [25]. The involved CYP isoforms in the enzymatic 
demethylation of glaucine were as follows: CYP1A2, CYP2C19, CYP2D6, CYP3A4, and 
CYP3A5. All kinetic profiles could be modeled using the Michaelis-Menten equation. For 
all enzyme kinetics (CYPs, HLM), the metabolite formation approach using calibration 
with the corresponding synthesized reference standards was applied and compared to 
the results to those obtained by arbitrary units. The bias of the quantification approach 
for assessing the contribution of CYPs to hepatic clearance and therefore to the hepatic 
net clearance in vivo was negligible. In conclusion, the determination method had no 
substantial impact on the estimation of in vivo hepatic clearance of glaucine. Further 
inhibition experiments in HLM with specific and selective inhibitors confirmed the results 
of the contribution of the involved CYPs. Using the Michaelis-Menten equation and 
determined pharmacokinetic constants, concentration-dependent involvement of CYP 
isoforms was calculated for different glaucine concentrations (0.1-100 µM) according to 
Meyer et al. [72]. In a case report of recreational glaucine use [42], plasma levels of 0.7 
mg/L (2 µM) were documented. Over the tested concentration range, only minor 
variations in the enzyme contributions were observed. The overall contribution of all 
CYP-catalyzed metabolic steps was as follow: CYP3A4 was about 79 %, of CYP1A2 18 
%, of CYP2D6 2 %, and of CYP2C19 <1 % determined for a glaucine concentration of 5 
µM. As glaucine was metabolized via three main steps and different CYP isoforms were 
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involved in the hepatic clearance of glaucine, a clinically relevant interaction with single 
inhibitors should not be expected. Over the last years, many studies have been 
published regarding the impact of interactions with drugs of abuse, therapeutically 
administered drugs, food ingredients, and/or tobacco smoke ingredients as well as of 
genetic variations [2, 73-75]. For assessment or prediction of all these variations, it is 
important to know whether an individual has a reduced or an increased turnover in 
these steps due to genetic variations or due to drug/food interactions by enzyme 
inhibition or induction. Such interactions are of general interest also in drug abuse 
because many drug users suffer from polytoxicomania with higher risk of drug 
interactions. Clinical or case studies are necessary for final assessment of the clinical 
relevance. 
The developed isolation method for the Sceletium alkaloids allows simple and effective 
extraction and purification of both main alkaloids mesembrine and mesembrenone [62, 
75]. The presented metabolism study has shown that mesembrine and mesembrenone 
were extensively metabolized by hydroxylation, dealkylation, dihydration, N-oxidation, 
and combinations of them. The main metabolites were confirmed in human liver 
preparations (HLM, HLC) and the following CYPs were determined: O-demethylation of 
mesembrine was catalyzed by CYP1A2, CYP2B6, CYP2C19, and CYP2D6 and the N-
demethylation by CYP1A2, CYP2B6, CYP2C19, CYP2D6, CYP3A4, and CYP3A5. The 
O-demethylation of mesembrenone was catalyzed by CYP2C9, CYP2C19, and 
CYP2D6 and the N-demethylation by CYP2C19, CYP2D6, and CYP3A4 [62]. For the 
detectability studies, a 1 mg/kg BM dose were administered to rat and the urine was 
collected over a 24 h period. Using the GC-MS screening approach, the acetylated 
demethyl-dihydro and hydroxy metabolite of mesembrine, and the acetylated demethyl-
dihydro mesembrenone metabolite could be detected. The main targets in the LC-MSn 
screening approach for mesembrine were also the O- and N-demethyl-dihydro, and the 
bis-demethyl-dihydro metabolites, for mesembrenone only the N-demethyl- and the N-
demethyl-dihydro metabolite and in addition their glucuronides. 
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4. Summary 
 
In the presented studies, the metabolism and the toxicological detection of glaucine and 
the Sceletium tortuosum alkaloids mesembrine and mesembrenone were investigated. 
Glaucine was mainly O- and N-dealkylated in rats and further conjugated to 
glucuronides or sulfates. The phase I metabolites were synthesized and further in vitro 
experiments with HLM confirmed the formation of the metabolites in humans. The 
following CYP isoforms were mainly involved in these reactions: 1A2, 2C19, 2D6, 3A4, 
and 3A5. The kinetic profiles of all metabolite formations followed classic Michaelis-
Menten behavior. The Km values were between 25-140 µM and the Vmax values 
between 0.10 - 1.92 pmol/min/pmol. Toxicological detection should be focused on the 
demethyl-dehydro metabolites and the corresponding glucuronides and/or sulfates. 
Mesembrine and mesembrenone were also extensively metabolized in rat. The main 
metabolic pathway is a combination of demethylation and reduction of the keto function. 
The phenolic metabolites were partly excreted as glucuronides or sulfates. The phase I 
metabolites could also be found in human liver preparations. Demethylation of 
mesembrine was catalyzed by following CYPs: 1A2, 2B6, 2C19, 2D6, and 3A4 and the 
demethylation of mesembrenone by 2C9, 2C19, 2D6, and 3A4. The main analytical 
targets for the toxicological detection were the demethyl-dehydro metabolites and in 
case of LC-MSn, the corresponding glucuronides and/or sulfates. 
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6. Abbreviations 
 
5-HT serotonin 
ADH alcohol dehydrogenase 
AU arbitrary units 
BM body mass 
CC column chromatography 
CNS central nervous system 
COMT catechol-O-methyltransferase 
CYP cytochrome P450 
DA dopamine 
DM demethyl 
EMEA European Medicines Agency 
FDA US Food and Drug Administration 
GC gas chromatography 
HLC human liver cytosol 
HLM human liver microsomes 
HR high resolution 
IR infrared 
IS internal standard 
LC liquid chromatography 
LLE liquid-liquid extraction 
MS mass spectrometry 
NAT N-acetyltransferase 
NMR nuclear magnetic resonance spectroscopy 
PDE phosphodiesterase 
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SPE solid-phase extraction 
SULT sulfotransferase 
UGT uridine diphosphate glucuronyltransferase 
UN United Nations 
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7. Zusammenfassung 
Die vorliegende Dissertation umfasst Untersuchungen zum Metabolismus und 
Nachweisbarkeit der Alkaloide Glaucin, Mesembrin und Mesembrenon.  
Glaucin wurde in der Ratte hauptsächlich zu vier Phase-I-Metaboliten O- und N-
desalkyliert und anschließend zu Glucuronide oder Sulfaten konjugiert. Die Phase-I-
Metaboliten wurden synthetisiert und deren Struktur mittels NMR-Techniken aufgeklärt. 
Weitere in-vitro-Experimente mit HLM bestätigten die Bildung der Metaboliten im 
Menschen. Folgende CYP-Isoformen waren an den Reaktionen beteiligt: 1A2, 2C19, 
2D6, 3A4 und 3A5. Die resultierenden Km Werte lagen zwischen 25 - 140 µM und die 
Vmax Werte zwischen 0.1 - 1.9 pmol/min/pmol. Der analytische Fokus für die 
Nachweisbarkeit sollte auf den demethylierten Metaboliten und auf den zugehörigen 
Glucuroniden und/oder Sulfaten. 
Mesembrin und Mesembrenon wurden von der Ratte stark metabolisiert. Beide 
Alkaloide werden hauptsächlich demethyliert und reduziert. Alle phenolischen 
Metaboliten werden teilweise als Glucuronide oder Sulfate ausgeschieden. Die Phase-I-
Metaboliten konnten in in-vitro-Experimenten mit humanen Leberpräparationen belegt 
werden. Die Demethylierungen des Mesembrins wurden durch folgende CYP isoformen 
katalysiert 1A2, 2B6, 2C19, 2D6 und 3A4 und die des Mesembrenons durch 2C9, 2C19, 
2D6 und 3A4. Der analytische Fokus für die Nachweisbarkeit sollte auf den 
demethylierten und reduzierten Metaboliten liegen und auf den zugehörigen 
Glucuroniden und/oder Sulfaten. 
 
